Clinical Trial Update: A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase II trial results assess the combination of panobinostat and lenalidomide in patients with relapsed or refractory Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Panobinostat (Panobinostat)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-14